Obesity drug submitted for approval in Japan, Novo Nordisk reports

Novo Nordisk is now aiming to have its weight loss drug Wegovy approved in Japan. In Wednesday's quarterly report, the pharmaceutical company announces that it submitted the marketing application to the Japanese authorities back in August.

Photo: Novo Nordisk / PR

In August, a marketing authorization application for the obesity drug Wegovy was sent off to the Japanese authorities (PMDA), Novo Nordisk reveals in its quarterly report for the third quarter.

Wegovy, which is built on the GLP-1 analog semaglutide, has been out in the US since June of this year, while a decision from the European Medicines Agency (EMA) is expected around the New Year.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs